MORTALITY AND COMPLICATION OF PATIENTS WITH RA

Yasuharu Nakashima1

Results: The mortality within 30 and 90 days were 21.4% (15/70) and 27.1% (19/70), respectively, and 24 of 65 patients (36.9%), excluded 5 patients with RA (68) or JIA (2) staying at the ICU of our institution between January 2008 and March 2018, 70 patients (20 males, 50 females) with RA (68) or JIA (2) required the intensive treatment. Severe infections are among the most common causes of their mortality in intensive care unit (ICU)12.2. The average of age at the admission and RA duration was 65.8±5.8 vs 4.5±4.9), Charlson Comorbidity Index3) (5.1±2.5 vs 4.0±1.4), and patients with rheumatoid arthritis (RA) are associated with high mortality caused by comorbidity and complication, and are often required the intensive treatment. Severe infections are among the most common causes of their mortality in intensive care unit (ICU)12.2.

Objectives: To determine prognostic factors and mortality in patients with RA, including juvenile idiopathic arthritis (JIA), admitted to the ICU in Kyushu University Hospital, we examined the treatments of RA and JIA, comorbidities, complications, the reasons admitted to the ICU, intensive treatments, mortalities within 30 days, 90 days, and a year.

Methods: Between January 2008 and March 2018, 70 patients (20 males, 50 females) with RA (68) or JIA (2) staying at the ICU of our institution for 48 hours and over were included in this study. The admission to the ICU were performed total 77 of times because 5 patients were readmitted. The average of age and RA duration at the admission was 65.8±5.8 years (5-96) and 13.5±14.8 years (0-61), respectively, and the average of follow-up duration was 879.9±992.0 days (3-3988). ±17.7 years (5-96) and 13.5±14.8 years (0-61), respectively, and the average of age and RA duration at the admission was 65.8±5.8 years (5-96) and 13.5±14.8 years (0-61), respectively, and the average of follow-up duration was 879.9±992.0 days (3-3988). ±17.7 years (5-96) and 13.5±14.8 years (0-61), respectively, and the average of age and RA duration at the admission was 65.8±5.8 years (5-96) and 13.5±14.8 years (0-61), respectively, and the average of follow-up duration was 879.9±992.0 days (3-3988).

Conclusion: Our study has shown the high mortality of RA patients admitted to the ICU, and some blood data could be predicted poor prognosis.

REFERENCES

Disclosure of Interests: None declared

Table 2. Multivariate analyses of BRAFT-MDO and its subscales. p < 0.001, *p < 0.05. Cells represent beta coefficients with standard error

<table>
<thead>
<tr>
<th>Physical</th>
<th>Living</th>
<th>Cognitive</th>
<th>Emotional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>-0.10</td>
<td>0.00 (0.04)</td>
<td>-0.00 (0.03)</td>
</tr>
<tr>
<td>Sex</td>
<td>-2.65</td>
<td>1.70 (-1.90)</td>
<td>-2.45 (1.13)**</td>
</tr>
<tr>
<td>RA positive</td>
<td>3.80 (1.15)</td>
<td>2.45 (1.13)**</td>
<td>-1.83 (0.90)**</td>
</tr>
<tr>
<td>Non Anti-TNF</td>
<td>3.33 (1.18)**</td>
<td>2.60 (1.23)**</td>
<td>0.02 (0.01)**</td>
</tr>
<tr>
<td>DAS28-ESR</td>
<td>1.75 (0.65)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>Good Sleep quality</td>
<td>-2.75 (1.10)**</td>
<td></td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

Table 1. Demographic and clinical characteristics of RA according to BEI groups.

<table>
<thead>
<tr>
<th>BEI = 0</th>
<th>BEI &lt; 30</th>
<th>BEI &gt; 30</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, n (%)</td>
<td>120 (92.3)</td>
<td>72 (91.1)</td>
<td>71 (94.7)</td>
</tr>
<tr>
<td>BEI hours/year</td>
<td>0 (0-0)</td>
<td>15 (2-19)</td>
<td>72 (42-160)</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>32 (24.8)</td>
<td>19 (24.4)</td>
<td>33 (44.0)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>32 (24.4)</td>
<td>21 (26.6)</td>
<td>33 (44.0)</td>
</tr>
<tr>
<td>Body mass index, kg/m2</td>
<td>27.66 (25.07-27.25)</td>
<td>25.23 (24.32-25.61)</td>
<td>27.83 (25.52-27.61)</td>
</tr>
<tr>
<td>Disease Duration, years, median</td>
<td>9.03 (9.5-9.5)</td>
<td>9.04 (9.3-9.5)</td>
<td>9.04 (9.3-9.5)</td>
</tr>
</tbody>
</table>

Conclusion: In our cohort of Mexican-mestizo RA subjects, 54% had positive biomass exposure. Subjects with a BEI >30 were older and had a higher prevalence of dyslipidemia and hypertension. A significant correlation was found between higher BEI index and a higher value of ACPA antibodies.

Disclosure of Interests: None declared

Table AB0322. Biomass smoke exposure linked to higher ACDA levels in Mexican-mestizo RA-patients.

Dionicio Angel Galaz-Polanco1, Iris Jazmin Colunga-Pedraza1, Jose Ramon Azpr-Perez2, Yeana Cecilia Reynosa-Silva2, Raymundo Pineda2, Karla Paola Cuclier-Calderon1, Margarita Castro-Gonzalez2, Carolina Marlene Martinez-Flores2, Alberto Cardenas1,1 Hospital Universitario “Dr. José Eleuterio González”, UANL, Rheumatology, Monterrey, Mexico; 2Hospital Universitario “Dr. José Eleuterio González”, UANL, Cardiology, Monterrey, Mexico.

Background: Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease of the joints. Current classification criteria for RA diagnosis requires the presence of either rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). These have also been linked to chronic air pollutants exposure, such as tobacco smoke and biomass fuel smoke. Patients with COPD and biomass exposure have higher levels of ACPA (1). Nearly 50% of the world’s population still rely on biomass fuels for cooking, heating and industry, especially in low-income countries (2).

Objectives: To investigate the prevalence of biomass exposure in a cohort of Mexican-mestizo RA-subjects, and the effect of it in their RF and ACPA levels.

Methods: A cross-sectional, observational trial with RA-subjects that fulfilled the 2010 ACR/EULAR classification criteria, recruited at a rheumatology clinic in northeastern Mexico. Patient evaluation included a complete clinical history, somatometry, and blood samples to measure hs-CRP, RF isotypes (IgA, IgG, IgM) and ACPA. Biomass exposure was documented using the biomass exposure index (BEI), defined as: average hours exposed per day multiplied by years of exposure. Descriptive statistics was done using frequencies (%) and median values (q25-q75). Subjects were divided into 3 groups according to their BEI: non-exposed, BEI <30 and BEI >30. Comparisons were done by Chi-square and Kruskal-Wallis test and correlation by Spearman’s rho test.

Results: A total of 285 subjects were included, 154 (54%) of them had history of exposure. Comparisons are shown in Table 1. A significant difference in age was found (p=0.006), this being caused by a difference between the BEI=0 and BEI >30 groups (p=0.001). We also found a higher prevalence of dyslipidemia and hypertension in subjects with a BEI >30 (p=0.05). A significant correlation between a rising BEI and a higher value of ACPA (r=0.14, p=0.016) was found; this correlation was not found with any subtype of RF (p=0.05).

Disclosure of Interests: None declared

Table AB0322.

Disclosure of Interests: None declared

Downloaded from http://ard.bmj.com/ on October 31, 2023 by guest. Protected by copyright.
AB0323

CARDIOVASCULAR RISK ESTIMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICS OR C-DMARDs

Evangelia Mole1, Sousana Gazi1, Dimitra Moschou1, Georgia Paili1, Stavros Theodorakopoulos2, Konstantina Zoupidou1, Nikolaos Kontodimopoulos2, 1KAT General Hospital of Attica, Department of Rheumatology, Athens, Greece; 2KAT General Hospital of Attica, Division of Management, Athens, Greece

Background: Patients with Rheumatoid Arthritis (RA) are at increased risk of developing atherosclerotic cardiovascular (CV) disease. The impact of treatment with conventional or biological disease modifying drugs (c- or b-DMARDs) on inflammation of systemic circulation is an important question.

Objectives: The aim of this study is to determine the influence of therapy (c-DMARDs or b-DMARDs) on 10 year CV risk in patients with RA over a period of 18 months.

Methods: A single center, observational study of 229 consecutive RA patients, who were treated with c-DMARDs or b-DMARDs mono/combination therapy for at least 18 months. The 10 year CV risk was calculated with Framingham risk score (FRS).

Results: A total of 229 patients were included, 111 received b-DMARDs and 194 c-DMARDs. The mean age was comparable between 2 groups (62.4±9.17 vs 64.56±12.48 years, p: 0.1596) and 148 (64.63%) were females. Patients receiving b-DMARDs had longer disease duration compared to c-DMARDs group (14.3±9.3 years vs 9.99±9.3 years respectively, p: 0.001) and compared to baseline FRS 10-year percent CV risk (10.74±8.88 vs 11.68±7.88 respectively, p: 0.3710). Baseline patient distribution across intermediate (9.6% vs 16.6%) and high (10.91% vs 16.16%) FRS 10-year CV risk categories was comparable between treatment groups (b-DMARDs vs c-DMARDs, p: 0.208), except low FRS category (27.51% vs 51.53% respectively, p<0.001). At month 18, FRS 10-year CV risk category remained stable in b-DMARDs patients (low: 31.68%, intermediate: 10.92%, high: 5.24%, p: 0.47), whereas a significant shift in FRS 10-year CV risk category was observed in c-DMARDs patients (low: 58.1%, intermediate: 17.03%, high: 9.17%, p: 0.001). Within-group the mean (SD) change in FRS 10-year percent CV risk from baseline to month 18 was statistically significant for both b-DMARDs (Δ: 10.74±9.94–1.8 (1.14, p<0.001)) and c-DMARDs (Δ: 11.68±7.87–2.95 (0.91), p<0.001).

Conclusion: Patients treated with b-DMARDs had lower baseline and month 18 10-year CV risk. However, both treatment arms induced significant improvement of 10-year CV risk at 18 months.

REFERENCES

AB0325

PREVALENCE OF ANXIETY/DEPRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS AT THE UNIVERSITY OF CHILE’S CLINICAL HOSPITAL AND THEIR ASSOCIATIONS WITH DISEASE ACTIVITY INDEXES AND QUALITY OF LIFE

Anne Marie Chassin-Troubetz1, César Lillo1, Stephanie Prieto1, Ariel Castro2, Hector Gatica1, Pilar Carrasco1, Francisca Bozari1, Francisca Salbijo1, Pamela Wurman2, Julio Cruz1, Silvana Saavedra1, Annelsee Goecke3, 1Hospital Clínico Universidad de Chile, Rheumatology, Santiago, Chile; 2Hospital Clínico Universidad de Chile, OAIC, Santiago, Chile

Background: Rheumatoid Arthritis is a chronic inflammatory disease with great impact in quality of life. Anxiety and depression could be frequently present in RA patients and may impact the disease activity evaluation. However psychological evaluation or therapy are not part of the standard of care of RA patients.

Objectives: To evaluate the prevalence of anxiety/depression in rheumatoid arthritis patients in control at the University of Chile’s Clinical Hospital and to investigate the association of anxiety/depression with disease activity and quality of life.

Methods: The Hospital Anxiety Depression Scale (HADS) was applied to measure depression and anxiety in a cross-section patients with RA meeting the ACR/EULAR 2010 criteria in control at the University of Chile’s Clinical Hospital. All patients included gave their inform consent. Demographic characteristics, Disease variables and activity, measure as DAS28-VHS, DAS-28 CRP, CDAI and SDAI and HAQ were evaluated at the same time. Spearman correlation, Fisher exact test, Chi-Square and Kruskal-Wallis test were used according to variables at evaluation. Statistical analysis was perform by Stata v12.1 software. The study was approved by the Hospital Ethic Review board.

Results: 123 patients were enrolled in the study between december 2017 and December 2018. 103 (84.45%) were female. 56 (46%) had depression and/or anxiety according to HADS. 24% of the patients (n=24) had severe anxiety symptoms respectively. The disease activity was significantly higher in patients with anxiety and/or depression (p<0.01).

Disclosure of Interests: None declared


AB0324

PAIN IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BARICITINIB: RESULTS OF A PROSPECTIVE STUDY

Ricardo Juan Gil Velez1, Clara Aguilera Crios1, Alberto Ruiz Roman1, Lara Mendez Diaz1, Elena Alonso Morales1, Esteban Rubio Romero1, Juan Povedano Gomez1, Sevilla, Seville, Spain

Background: Assessment of pain improvement during treatment for Rheumatoid Arthritis (RA) may be useful to clinical decision between providers and their patients.

Baricitinib (BARI) once daily, an oral, selective Janus Kinase (JAK)1/2 inhibitor, reduced disease activity levels in Rheumatoid Arthritis (RA) patients (pts) with an inadequate response (IR) to methotrexate (MTX).

Objectives: To Evaluate the likelihood of achieving different levels of pain control with BARI 2 mg or 4 mg in patients with RA with inadequate response to traditional DMARDs or biological DMARDs.

Methods: Prospective observational registry of pts with RA who start treatment with BARI, in a third level Spanish Hospital (October 2017- June 2018). BARI 2 mg is started in several in patients with inadequate response to traditional DMARDs and BARI 4 mg in patients with inadequate response to biological DMARDs. The pts were assessment of pain was assessed with 0-100 mm visual analog scale (VAS) at each study visit. The likelihood of achieving >=25%, >=50% and >=70% pain VAS improvement through week 12 and analyze if there are significant differences between the group of patients with BARI 2 mg and BARI 4 mg (Mann-Whitney test). The statistical study was carried out with the SPSS15 computer package.

Results: We included 38 pts (28 women), mean age 52 ± 12 years. Pain VAS improvement for all patients, baseline pain and weeks 12. The frequency is the percentage of improvement with respect to the baseline. In BARI 2 mg group, 58% of pts (p<0.05) have experienced a decrease greater than pain VAS improvement than baseline and in BARI 4 mg group 91% of pts (p<0.05) have experienced a decrease greater than pain VAS improvement than baseline.

No statistically significant differences were found in the two treatment groups (BARI 2 mg and BARI 4 mg) (p 0.847).

Conclusion: Our results, in general, agree with what is published in the literature (RA treated with BARI reported greater improvements in pain control when compared to adalimumab or placebo, a post-hoc analysis of the Phase 3 RA-BEAM study). BARI treated pts reported significantly greater and more rapid reductions in pain severity as measured by the pain VAS, improvements were sustained 12 weeks, without finding differences in pts receiving BARI 2 mg or BARI 4 mg.

Disclosure of Interests: None declared